Diffusely increased F-18FDG uptake in bone marrow in a patient with acute anemia and recent erythropoietin therapy

被引：31
作者：
Plantade, A
Montravers, F [1 ]
Selle, F
Izrael, V
Talbot, JN
机构：
[1] Hop Tenon, Dept Nucl Med, F-75970 Paris, France
[2] Hop Tenon, Dept Oncol, F-75970 Paris, France
来源：
CLINICAL NUCLEAR MEDICINE | 2003年 / 28卷 / 09期
关键词：
FDG; bone marrow; anemia; erythropoietin;
D O I：
10.1097/01.rlu.0000082670.19100.83
中图分类号：
R8 [特种医学]; R445 [影像诊断学];
学科分类号：
1002 ; 100207 ; 1009 ;
摘要：
Diffuse uptake of F-18 fluorodeoxyglucose (FDG) by the whole skeleton has been described in case of bone marrow stimulation resulting from treatment with colony-stimulating factors (CSFs): granulocyte CSF or granulocyte-macrophage CSF. The authors describe such an aspect of diffuse FDG uptake by the bone marrow during the follow-up of rectal cancer in a patient with anemia and recently treated thrice weekly by erythropoietin. To their knowledge, such an aspect of diffuse FDG uptake by the skeleton, revealing the bone marrow stimulation by erythropoietin, has not yet been reported.
引用
收藏
页码：771 / 772
页数：2
相关论文
共 8 条
  • [1] Granulocyte colony-stimulating factor - Confounding F-18FDG uptake in outpatient positron emission tomographic facilities for patients receiving ongoing treatment of lymphoma
    Gundlapalli, S
    Ojha, B
    Mountz, JM
    [J]. CLINICAL NUCLEAR MEDICINE, 2002, 27 (02) : 140 - 141
  • [2] Hematopoietic cytokine-mediated FDG uptake simulates the appearance of diffuse metastatic disease on whole-body PET imaging
    Hollinger, EF
    Alibazoglu, H
    Ali, A
    Green, A
    Lamonica, G
    [J]. CLINICAL NUCLEAR MEDICINE, 1998, 23 (02) : 93 - 98
  • [3] Bone marrow uptake of fluorine-18-fluorodeoxyglucose following treatment with hematopoietic growth factors: Initial evaluation
    Knopp, MV
    Bischoff, H
    Rimac, A
    Oberdorfer, F
    vanKaick, G
    [J]. NUCLEAR MEDICINE AND BIOLOGY, 1996, 23 (06): : 845 - 849
  • [4] Mayer D, 2002, ANN PHARMACOTHER, V36, P1796
  • [5] Assessing the clinical significance of health-related quality of life (HrQOL) improvements in anaemic cancer patients receiving epoetin alfa
    Patrick, DL
    Gagnon, DD
    Zagari, MJ
    Mathijs, R
    Sweetenham, J
    [J]. EUROPEAN JOURNAL OF CANCER, 2003, 39 (03) : 335 - 345
  • [6] Ponchio L, 2000, HAEMATOLOGICA, V85, P219
  • [7] Use of epoetin in patients with cancer: Evidence-based clinical practice guidelines of the American Society of Clinical Oncology and the American Society of Hematology
    Rizzo, JD
    Lichtin, AE
    Woolf, SH
    Seidenfeld, J
    Bennett, CL
    Cella, D
    Djulbegovic, B
    Goode, MJ
    Jakubowski, AA
    Lee, SJ
    Miller, CB
    Rarick, MU
    Regan, DH
    Browman, GP
    Gordon, MS
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2002, 20 (19) : 4083 - 4107
  • [8] Preclinical and clinical studies of bone marrow uptake of fluorine-18-fluorodeoxyglucose with or without granulocyte colony-stimulating factor during chemotherapy
    Sugawara, Y
    Fisher, SJ
    Zasadny, KR
    Kison, PV
    Baker, LH
    Wahl, RL
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 1998, 16 (01) : 173 - 180
1